Login or Register to view
Investment Highlights
-
Emerging global leader in the growing US$33B Medical Device and Technology, Rapid Test Market
-
Neopharma Technologies is recognised as a Top 100 Medical Device and Technology company globally
-
TamperLoks DataVault is a globally patented Drugs of Abuse testing solution
-
US FDA Regulatory pathway breakthrough with US market access for TamperLoks anticipated Q1 2023.
Company Overview
-
Extensive Intellectual Property
Portfolio of patents and trademarks patents for an extensive range of medical devices
-
myNEO
World’s first Covid-19 testing app, integrated for all TGA and US FDA approved rapid antigen test kits
-
NEOVAULT
ERM technology platform providing an accurate, safe and secure way to manage health testing programs.
Leader in medical device technology
Neopharma’s goal is to be a recognized global leader in the growing US$33B Medical Device and Technology, Rapid Test Market and $2.9B Track-and-Trace market.
Neopharma has produced a range of innovative rapid tests for Drugs-of-Abuse with its global patented TamperLoks and next-generation Saliva Drug Test NEOSWAB+ and Saliva Drug and Alcohol Test NEOSWAB DA+.
Also under development is a range of other rapid tests covering infectious disease, pregnancy and Covid-19/Flu.
The company has a US FDA Regulatory pathway for TamperLoks, anticipated in Q1 2023, and has secured Letters of Authorisation with leading Medical device manufacturers globally, with a number of KPI driven distribution agreements.
High-growth industry sector
Neopharma Technologies Ltd is an Australian public company in the US$33B Rapid Test Market and high growth Market.
Neopharma’s market-leading, patented TamperLoks medical device and next-generation Saliva Drug Test NEOSWAB+ and Saliva Drug and Alcohol Test NEOSWAB DA+, have significant market potential, along with its other range of products.
Extensive IP & patents
Neopharma Technologies has an extensive intellectual property portfolio having secured patents and trademarks for its range of medical devices and supporting technologies.
The company is launching its Drug testing and rapid testing products globally in 2023 with its focus on the USA and AUS markets.
Products & Services
NEOTEST & myNEO: the World’s first Covid-19 testing app
Designed by Neopharma Technologies used with all US FDA and TGA-approved Covid-19 antigen and combined Covid-19 antigen & Flu AB test kits for the US and Australian markets.
Drugs-Of-Abuse Testing – Tamperloks Datavault
TamperLoks enables a rapid drugs-of-abuse urine test and assigns a unique QR code to the candidate being tested.
TamperLoks DataVault is a global leader in drugs-of-abuse testing. There is no current comparable hardware and technology pairing in the market globally.
Tamperloks – Rapid Drug Test Device
Patented 3-chamber tamperproof drugs-of-abuse urine testing device.
Test results within 90 seconds.
Patents ensure asset protection with further expansion into new markets.
Transaction Overview
Pre-IPO offer at 30 cents per share with a 1 for 1 free attaching option, exercisable at 30 cents with 2 years expiry.
Targeting an ASX listing in Q2 2023.
Team
- Management
- Directors
-
Gajenddra Raj
Chief Technical Officer
-
Nikhil Kothari
General Manager
-
Jason Yeun
Chief Manaufacturing Engineer
-
Marcus L’Estrange
Executive Chairman
-
Shaun Melville
Executive Director
-
Neel Le Roux
Non-Executive
-
Non-Executive
Want to learn more?
Fill in the expression of interest form below
Speak to our investment team today
+61 2 9993 4475